Bengaluru, India

27th July 2019

 All PhUSE Single Day Events are FREE to members. To become a member click here. Registrations per company are limited to 20% of maximum attendance.



Industry 4.0: Avoiding Digitization and Modernization 'Not an Option'



We believe that digitalization is no longer a choice but an obligation if you want to remain competitive in the market. Some entrepreneurs will argue that their industry is different and that they are not affected by digital transformation, but this is not logical since everything is affected by digital innovation. Innovation and investments in research and development involve radical changes in all business processes. Ignoring the technological changes and failing to adapt to them gives space to those competitors who have already understood that digitization is not a choice or something that can be used partially. Those who do not digitalize will end up being overtaken, left behind and eventually expelled from the market. This new business model is not a simple prediction: it is already a reality.

The next decade promises both tremendous potential and significant disruption for the biopharmaceutical industry, as companies transition their focus from blockbuster products and volume-based models to specialty products and value-based models. Both science and development operations are becoming increasingly more complex, with an average drug development cost of $2.6 billion per product. As development costs and complexities soar, stakeholder (patients, investigators, payers, etc.) expectations continue to evolve at pace, with technology advancements creating the need for a more convenient and personalized approach for products. Fortunately, new digital technologies exist to optimize the clinical development process, and, more broadly, the entire research and development value chain. Research shows that digitalization will be fueling one-third of the growth and an estimated 40 percent of the profitability in the pharmaceutical market by 2020. Research and development executives recognize digital as a primary driver to deliver patient outcomes, and companies that embrace digital report stronger performance across several key R&D capabilities.



 To follow shortly



 To follow shortly


SDE Chair:

Ranjith Prayankotveettil, PPD

If you have any questions, or require any information, please contact the SDE Chair.






If you are interested in sponsoring this event, click here.


How Do I Join the PhUSE Society?

There are two easy ways to join PhUSE:

1. Register online.

2. Contact for group membership applications or for invoicing arrangements.



Thinking of joining PhUSE?

Already a member but not sure how you can benefit?

PhUSE is an expanding, global society with a membership of more than 8,000 clinical data scientists. It requires a large pool of resources to help with its running so offers many opportunities for members to become involved. Whether it's chairing a conference, presenting at an event, leading a working group or contributing to the quarterly newsletter, we are always keen to hear from volunteers.

Find Out More